Oct 4, 2018 · This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody–drug conjugate of the anti–c-Met monoclonal antibody ABT-700 and monomethyl auristatin E.

Feb 15, 2017 · ABBV-399 inhibits growth of xenograft tumors refractory to other c-Met inhibitors and provides significant therapeutic benefit in combination with standard-of-care chemotherapy.

Second- and third-line Tx options are limited to chemotherapy-based regimens with limited efficacy and significant toxicities. Teliso-V (ABBV-399), an anti–c-Met antibody-drug conjugate, delivers a cytotoxic payload (monomethyl auristatin E) into c-Met OE tumor cells.

Oct 1, 2019 · T (teliso-v, ABBV-399) is a first-in-class c-Met specific antibody drug conjugate that is cytotoxic to cancer cells with overexpressed c Met and demonstrates antitumor activity in human tumor xenografts.

Telisotuzumab vedotin (Teliso-V; ABBV-399) is an anti–c-Met ADC composed of the monoclonal antibody ABT-700 and the microtubule inhibitor monomethyl auristatin E (MMAE).

This first-in-human study evaluated telisotuzumab ve dotin (Teliso-V), formerly called ABBV-399, an antibody–drugconjugateoftheanti–c-MetmonoclonalantibodyABT-700andmonomethylauristatinE. Materials and Methods

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met.

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met.

Background: Teliso-V is a c-Met–targeted antibody and MMAE drug conjugate, with a t 1/2 of ∼2–4 days. We updated data analyses of T schedule of administration (q2w vs q3w) and T+E in c-Met+ NSCLC pts.

Nov 20, 2018 · Purpose: This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug conjugate of the anti-c-Met monoclonal antibody ABT-700 and monomethyl auristatin E.